Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379692 | 0.73 | ALDH1A1 (0.35) | ATMALDH1A1TSHRHPGDNAAA | |
| SCHEMBL19395340 | 0.72 | ALDH1A1 (0.43) | ATMALDH1A1TSHRHPGDHCAR2 | |
| SCHEMBL19395331 | 0.71 | ALDH1A1 (0.41) | ATMALDH1A1TSHRHPGDHCAR2 | |
| SCHEMBL19395351 | 0.69 | ALDH1A1 (0.45) | ATMALDH1A1TSHRHPGDHCAR2 | |
| SCHEMBL829195 | 0.69 | — | — | |
| Propene SCHEMBL11489185 | 0.68 | TSHR (0.42) | ATMALDH1A1TSHRHPGDHCAR2 | |
| SCHEMBL19395363 | 0.68 | EPHX1 (0.41) | ATMALDH1A1TSHRNAAA | |
| SCHEMBL20236 | 0.68 | CYP3A4 (0.42) | ATMALDH1A1TSHRHPGDHCAR2 | |
| Butane SCHEMBL1296581 | 0.67 | ALDH1A1 (0.41) | ATMALDH1A1TSHRHPGDHCAR2 | |
| SCHEMBL7126709 | 0.67 | ALDH1A1 (0.41) | ATMALDH1A1TSHRHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772519-B2 | Process for preparing mono-allyl-functionalized dialkylphosphinic acids, salts and esters thereof with allylic compounds, and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2014-07-08 | — | — | US | disclosed |
| US-20110224340-A1 | Method for Producing Mono-Vinylfunctionalized Dialkylphosphinic Acids, Salts and Esters Thereof, and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-15 | — | — | US | disclosed |
| US-20110213080-A1 | Process for Preparing Mono-Allyl-Functionalized Dialkylphosphinic Acids, Salts and Esters Thereof With Allylic Compounds, and the Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224340-A1 | Method for Producing Mono-Vinylfunctionalized Dialkylphosphinic Acids, Salts and Esters Thereof, and the Use Thereof | ACSL1, ACSL3, HACL2 | ATM 3143/4885ALDH1A1 2204/4885TSHR 1259/4885 |
| US-20110213080-A1 | Process for Preparing Mono-Allyl-Functionalized Dialkylphosphinic Acids, Salts and Esters Thereof With Allylic Compounds, and the Use Thereof | AGL, ACSL3, ACSL6 | ATM 3033/4885ALDH1A1 3349/4885TSHR 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.